Alerta

MEDICAL TEST RESULTS AND IDENTITY AUTHENTICATION SYSTEM AND METHOD

Resumen de: US20260196317A1

A system and method that enables users to provide authenticated medical records (e.g., vaccination records, viral anti-body test results, etc.) to a third-party (e.g., a venue) to gain access to the third-party is provided. In this way, the third party may confirm that the user is sufficiently immune to a particular disease (e.g., COVID-19) and may thereby minimize the threat of the user introducing the contagious disease to the third party. The system includes a biometric data recognition system that authenticates the identity of a user, a medical records acquisition system that acquires the medical records of the authenticated user, and a system for the displaying or otherwise providing the medical records to the third-party for review. The system also includes a system identification card that includes the user's contact information, alphanumeric characters associated with the user's driver's license number, medical records of the user, and other elements.

COMPOSITION FOR ANTIVIRUS COMPRISING NATURAL KILLER CELL

Resumen de: US20260193343A1

The present invention relates to an antiviral composition comprising Natural Killer (NK) cells as an active ingredient and, more particularly, to a composition for preventing or treating COVID-19 virus (SARS-COV-2) infection comprising NK cells as an active ingredient and a method for culturing lymphocytes comprising anti-COVID-19 virus NK cells.

PHARMACEUTICAL COMPOSITION FOR TREATING CORONOVIRUS INFECTIONS AND USE THEREOF

Resumen de: WO2026147882A1

The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease using pharmaceutical composition disclosed herein. Provided a new combinatorial drag or a new pharmaceutical composition comprising compound of Formula (II-I-W-B), and their use for the treatment or prevention of coronavirus infections, particularly the use for the treatment or prevention of infections caused by SARS-CoV-2 and mutants thereof.

B-CELL DEPLETION FOR SUPPRESSION OF ANTIBODY RESPONSES TO ONCOLYTIC VIRUS THERAPY

Resumen de: WO2026148353A1

Provided are methods of suppressing an anti-oncolytic virus (anti-OV) antibody response to an oncolytic virus (OV) therapy. The methods comprise administering a B cell-depleting agent to a subject (e.g., a human subject) prior to and/or concurrently with administration of a therapeutic OV to the subject. Non-limiting examples of B cell-depleting agents include those that target CD19 or CD20. In some instances, a B cell-depleting agent comprises or consists of an antibody. In certain embodiments, the therapeutic OV administered to the subject is from the family Poxviridae, Herpesviridae, Adenoviridae, Paramyxoviridae, Rhabdoviridae, Reoviridae, Picornaviridae, Parvoviridae, or Coronaviridae. According to some embodiments, the B cell-depleting agent is administered (e.g., only administered) prior to and/or concurrently with an initial administration of the therapeutic OV to the subject. OV therapies of interest include, but are not limited to, OV cancer therapies.

COMPOSITION FOR PREVENTION AND TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND INFLAMMATION

Resumen de: WO2026148343A1

Compositions and methods for protecting against a wide spectrum of viral and bacterial infections, including Covid-19, and for treating established infection and infectious inflammation are described. The composition includes a novel combination of vitamins, minerals, nutraceuticals, and phytochemicals, which may be compounded as a pill, tablet, powder, capsule or liquid to be taken orally or via other administration routs one or more times per day, to serve as immune boosters, antibacterial agents, and antiviral agents along with providing anti-inflammatory effects in humans and animals.

METHOD AND KIT FOR DETECTION OF POLYNUCLEOTIDE

Resumen de: US20260193700A1

The invention describes a kit for detection of a target polynucleotide using a CRISPR effector system that comprises CAS9 from Francisella novicida, a synthetic sgRNA and a detection scheme based on binding and subsequent enzymatic cleavage of the target polynucleotide. The invention also describes a method for detection of a target polynucleotide using the kit. The kit can be applied to both pathogenic and non-pathogenic polynucleotides and can be used to distinguish polynucleotides different by a single mismatch without the need for sequencing. The kit can also be used for detection of COVID-19. The kit is economical, easy to assemble and provides a robust and rapid readout that can be appropriately adapted for point of care applications.

METHOD FOR DETECTION OF SARS-COV-2 BY GOLD NANOPARTICLE ASSISTED LOOP MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) AND KITS THEREOF

Resumen de: US20260193724A1

0000 A method for the detection of SARS-CoV-2 in a sample based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) of a target nucleic acid sequence. The RT-LAMP amplicons are detected by gold nanoparticles (AuNPs) functionalized with a probe specific for regions of the target sequence. Kits for the detection of SARS-CoV-2 in a sample are also provided wherein the kit comprises a reverse transcriptase, a polymerase, a primer set for reverse transcription loop-mediated isothermal amplification (RT-LAMP) of the target sequence in a SARS-CoV nucleic acid sequence and variants thereof, and a conjugated nanoparticle solution comprising gold, water, and a probe sequence that is at least 85% identical to SEQ ID No.: 1.

SARS-CoV-2 Binding Antibody

Resumen de: US20260193327A1

0000 The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of antibodies.

PREPARATION METHOD FOR SALT OF CYCLIC CARBONATE NUCLEOSIDE COMPOUND AND CRYSTAL FORM THEREOF

Resumen de: EP4772515A1

The present invention belongs to the field of pharmaceutical technology and relates to a salt of a cyclic carbonate nucleoside compound, its crystal forms, preparation methods, and applications. The salt of the cyclic carbonate nucleoside compound has the structure shown in Formula I. When Y is hydrobromic acid and n=1, the salt of this nucleoside compound exists as Crystal Form A or Crystal Form B. Crystal Form A has advantages such as good physical and chemical stability, good solid properties, good water solubility, low hygroscopicity, and high oral bioavailability. It can be used to prepare drugs for treating and/or alleviating related diseases caused by viruses (particularly novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus, feline calicivirus, etc.).

METHOD AND DIAGNOSTIC KIT FOR MULTIPLE DETECTION OF VIRUSES OF THE FAMILY CORONAVIRIDAE: SARS-COV-2, SARS-COV, HCOV AND MERS-COV

Resumen de: EP3913069A1

0001 The invention relates to a diagnostic kit for multiple detection of 4 viruses of the Family Coronaviridae: HCoV, SARS-CoV, MERS-CoV and the SARS-CoV-2 viral strain that has caused a pandemic of the disease known as COVID-19. The kit uses a "One-Step" approach with quantitative gene amplification after backward transcription of the viral genome (rRT-PCR). 0002 In order to avoid potential false negatives, the invention contains a double control using Porcine Epidemic Diarrhoea Virus (PEDV -CoV) and Ribonuclease P (RNase P-RP).

DYRK/CLK PROTACS AND USES THEREOF

Resumen de: US20260183407A1

0000 The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLKI, CLK2, CLK3, CLK4, and HASPIN. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, and HASPIN, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer), a viral infection (e.g., SARS-COV-2 infection (e.g., COVID-19)), and other diseases.

IMMUNO-THERAPEUTIC CHEMICAL COMPOSITIONS AND USES THEREOF

Resumen de: WO2026142889A1

Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory -based disease and disorders comprising administration of ImmunoFolate.

GENETIC ENHANCEMENT OF EXOSOME PRODUCTION

Resumen de: US20260185108A1

0000 Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.

ANTI-SARS-COV-2 DRUG

Resumen de: WO2026141623A1

Provided is an antiviral drug that is effective against SARS-CoV-2.　Provided are: a compound represented by formula (I) (in the formula, Ar and R are as defined in the specification); a salt thereof; a solvate of these; a prodrug of these; and an anti-SARS-CoV-2 drug comprising these.

SEMISYNTHETIC GLYCOPEPTIDE ANTIBIOTICS WITH ANTIVIRAL ACTIVITY

Resumen de: WO2026139703A1

The present invention relates to compounds for use in the treatment of a disease or condition caused by Zika virus, Dengue virus, West Nile virus, Chikungunya virus, O`nyong`nyong virus, Sindbis virus or SARS-CoV-2 virus.

PAN-COVID-19 VACCINE COMPOSITION INCLUDING CONSENSUS SEQUENCE OF SARS-COV-2 VARIANTS

Resumen de: US20260183385A1

0000 Provided are a vaccine composition for pan-COVID-19 comprising a consensus sequence of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants.

SARS-COV-2 IMMUNOGENIC COMPOSITIONS AND METHODS

Resumen de: US20260183383A1

The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.

CORONAVIRUS-TARGETING BROAD-SPECTRUM BINDING-BLOCKING PROTEIN AND USE THEREOF

Resumen de: WO2026138823A1

Provided are a coronavirus-targeting broad-spectrum binding-blocking protein and a use thereof. Specifically, provided is a novel coronavirus Spike protein (S protein)-targeting binding protein having ultra-high affinity, wherein the protein can bind to an RBD area of the S protein and can block binding of a novel coronavirus to an ACE2 receptor, thereby blocking the novel coronavirus from invading host cells. Also provided is a novel coronavirus S protein-targeting self-assembling trimeric protein having high affinity, wherein the protein exhibits broad-spectrum blocking protection activity against novel coronaviruses.

SARS-CoV-2 Binding Polypeptide

Resumen de: US20260176302A1

The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of polypeptides.

METHODS, DIAGNOSTIC INSTRUMENTS, AND KITS FOR DETECTING DISEASES

Resumen de: US20260177549A1

0000 Provided herein are methods, diagnostic instruments, and kits for detecting the presence or absence of an analyte associated with a disease in a subject. In some embodiments, the disease is Lyme disease, SARS-CoV-2, or a human immunodeficiency virus infection.

NUCLEASE-DENDRIMER FORMULATIONS FOR COVID-19 AND BROAD-SPECTRUM ANTIVIRAL THERAPY AND PROPHYLAXIS

Resumen de: US20260174873A1

Compositions of nucleases in formulations with dendrimers are used in pharmaceutically effective dosages as therapeutics for covid-19 and a broad spectrum of viruses in various embodiments. When cationized nucleases are mixed and/or complexed with a dendrimer, an unexpected positive dendrimer effect is manifest. This positive dendrimer effect is shown to be highly effective for catalyzing anti-viral RNase properties. In various embodiments compositions of cationized nucleases in combination with a dendrimer demonstrated this synergistic amplification of anti-viral effectiveness and are used in pharmaceutically effective dosages as therapeutics against covid-19 and a broad spectrum of viruses. An exemplar formulation which exhibits a positive dendrimer effect is cationized RNase A mixed and/or complexed with gen 2 PAMAM dendrimer.

CELL-BASED FORMULATION CONTAINING PLURIPOTENT STEM CELLS FOR DISEASES OR POST-ACUTE SEQUELAE CAUSED BY SARS-COV-2 INFECTION

Resumen de: WO2026133815A1

This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and/or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and/or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.

NANOBODY-BASED LATERAL FLOW IMMUNOASSAY FOR RAPID ANTIGEN DETECTION

Resumen de: WO2026133305A2

A nanobody-based point-of-care lateral flow immunoassay (LFA) for the rapid, cost-effective detection of SARS-CoV-2 and MERS-CoV proteins in biological samples is disclosed. The assay described herein uses nanobody-based binding agents that selectively capture and detect viral antigens, such as spike (S) proteins and receptor-binding domains (RBDs), with high sensitivity and specificity. The LFA utilizes a colorimetric readout visible to the naked eye, eliminating the need for specialized equipment. The assay supports single and multiplex detection formats, enabling simultaneous analysis of multiple viral analytes. The LFAs are stable under standard storage conditions and provide a practical solution for decentralized and scalable testing.

SINGLE-DOMAIN ANTIBODIES INHIBITING VIRAL RNA POLYMERASE ACTIVITY

Resumen de: WO2026131760A1

The present invention relates notably to specific single-domain antibodies (sdAbs) targeting RNA-dependent RNA polymerase (RdRp) activity and their use in the prevention and/or treatment of a virus infection from Coronaviruses, and more particularly of SARS-CoV-2.

DIARYL HYDANTOIN COMPOUNDS AND USES THEREOF

Nº publicación: WO2026132293A1 25/06/2026

Solicitante:

UPPSALA UNIV PROJEKT AB [SE]
ATEA PHARMACEUTICALS INC [US]
UPPSALA UNIVERSITET PROJEKT AB
ATEA PHARMACEUTICALS, INC.